Belpointe Asset Management’s BioNTech BNTX Stock Holding History

Belpointe Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,359	Closed	-$1.04M	–	922
2023 Q1	$1.04M	Sell	8,359 -10,934	-57%	-$1.5M	0.06%	318
2022 Q4	$2.9M	Buy	19,293 +9,545	+98%	+$1.47M	0.18%	111
2022 Q3	$1.31M	Buy	+9,748	New	+$1.49M	0.09%	240

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belpointe Asset Management's BNTX Position: Q2 2023 in Review

Belpointe Asset Management sold out of BioNTech (BNTX) in Q2 2023, closing a stake of 8,359 shares — an estimated $1.04M sold.

Belpointe Asset Management first reported a position in BNTX in Q3 2022 and held it in 3 quarters. The position peaked at $2.9M in Q4 2022. 253 funds tracked by Wall St. Rank hold BNTX as of Q2 2023.

Belpointe Asset Management reported no remaining BioNTech position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 8,359 BioNTech shares in Q2 2023, an estimated $1.04M.
Belpointe Asset Management first reported a position in BioNTech in Q3 2022 and held it in 3 quarters.
Belpointe Asset Management's BioNTech position peaked at $2.9M in Q4 2022.
253 funds tracked by Wall St. Rank held BioNTech as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.